ArticlePharmaceutics2019
Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αChemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Cryptophycin unit B analogues.Beilstein journal of organic chemistry · 2025Article
- Oxime-Linked Peptide-Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview.International journal of molecular sciences · 2024Review
- Recent Advances in Cyanotoxin Synthesis and Applications: A Comprehensive Review.Microorganisms · 2023Review
- Multimeric RGD-Based Strategies for Selective Drug Delivery to Tumor Tissues.Pharmaceutics · 2023Review
- Versatile Applications of Cyanobacteria in Biotechnology.Microorganisms · 2022Review
- Synthesis and Evaluation of a Non-Peptide Small-Molecule Drug Conjugate Targeting Integrin αFrontiers in chemistry · 2022Article
- Review
- Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Cyanobacteria as Natural Therapeutics and Pharmaceutical Potential: Role in Antitumor Activity and as Nanovectors.Molecules (Basel, Switzerland) · 2021Review
- Synthesis and Biological Characterization of Monomeric and Tetrameric RGD-Cryptophycin Conjugates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2020Article
- Size-Dependent Cellular Uptake of RGD Peptides.Chembiochem : a European journal of chemical biology · 2020Article
- Bioactive Peptides Produced by Cyanobacteria of the GenusMarine drugs · 2019Review
- Conjugates of Cryptophycin and RGD orChemistryOpen · 2019Article
- Octreotide Conjugates for Tumor Targeting and Imaging.Pharmaceutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Cryptophycins are potent tubulin polymerization inhibitors with picomolar antiproliferative potency in vitro and activity against multidrug-resistant (MDR) cancer cells. Because of neurotoxic side effects and limited efficacy in vivo, cryptophycin-52 failed as a clinical candidate in cancer treatment. However, this class of compounds has emerged as attractive payloads for tumor-targeting applications. In this study, cryptophycin was conjugated to the cyclopeptide
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.